Living healthier for longer: the role of medical technology in Europe’s longevity challenge

For the longest of times medical breakthroughs have been celebrated for extending people’s lives. And rightly so. People are living much longer than anyone ever imagined they could, thanks in large part to modern healthcare practices. Most of us alive in Europe today reasonably expect to grow old. And yet few of us think about what kind of years we are adding as we grow old or that the challenges presented by an ‘ageing population’ are about us: We are the people getting older, living longer and in increasing numbers.

For many today, the extended years of life are dominated by years lived in dependency and frailty, with the looming prospect of enduring multiple chronic diseases, and the financial burden that goes with it. The dramatic increase in life expectancy has not been matched by an equivalent advance in health expectancy. Our success is creating a new policy challenge: how to help people live more of our well-earned, longer years in good health. That requires us to think differently about how we value healthcare innovation.

Lifespan vs health span

In his book ‘The Longevity Imperative’, Andrew J. Scott put the concept of ‘health span’ at the centre of public health policy debate. He argued that society has treated ageing as a problem to be managed with health systems, pension models, and careers built around the assumption of a short old age. Now we are stretching that old age out without redesigning the system around it. Scott’s alternative is an ‘evergreen agenda’ where the goal isn’t more years: It’s more healthier, engaged, productive years, available at every stage of life.

Arguably a much harder goal, but equally so much more rewarding, certainly for the individual who gets to compress the period of frailty and live a fully engaged life, but also for their loved ones who get to enjoy more of their company and for society as a whole who reap the benefits of a productive person’s contribution to their community or economy.

Minimally invasive care is one of the sharpest tools health systems already have for exactly that kind of compression. It often offers the possibility to have shorter procedures, reduced complication rates, faster mobilisation, preventative and personalised care, and fewer hospital-acquired complications. These advanced technologies are the practical ‘machinery’ by which a longer life becomes a longer healthy life.

Consider what is happening when a procedure changes from open surgery to minimally invasive. A patient who might once have faced weeks of hospitalisation and months of recovery can instead be home within days and back to independent living, caregiving, or work within weeks. That is not a marginal clinical footnote on the power of innovation, it’s the difference between a person spending a period of their life in dependency and spending that same period living it, with all the upside on productivity that comes with it. Multiply that experience by the millions of people undergoing procedures across Europe each year and the fact that these medical technologies are used at every stage of the care pathway (prevention, diagnostics, therapy, disease management and monitoring) then you start to see the potential impact on society and the evergreen agenda.

Reframing policy making

A health span lens complements existing assessments of safety, clinical effectiveness, cost and value by asking a broader question: does an innovation help people maintain health, independence and participation for longer?

That question speaks to policy debates already underway across Europe, from the evolution of Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR) to how we assess the full value of medical innovation, how it integrates into the care pathway and the broader challenge of making Europe an attractive place to bring medical innovation to patients. If Europe wants to support a society where longer lives mean more years of well-being rather than more years of managed decline, we have some work to do to reframe how we think about our healthcare systems and policy infrastructure.

Medical technology is already here and deployable

Medical technology alone can’t solve the ageing dilemma; I’m not saying that. It’s clear what is required is a much broader societal transformation. But medtech, and minimally invasive care in particular, has a legitimate claim to being one of the more immediately actionable pieces of that puzzle. The technology already exists. The clinical evidence already exists. What is still catching up is the policy architecture designed to recognise and reward the real value it creates to help make our gains in longevity, as Scott puts it, “the greatest gift humanity has ever been given”.